ASC30 A1

ASC30 A1 is an investigational formulation of **ASC30**, a novel, oral, small molecule **GLP-1 receptor (GLP-1R) biased agonist** developed by Ascletis Pharma. **ASC30 A1** is one of two oral tablet formulations under evaluation, designed for *once-daily use* in the management of obesity and overweight with weight-related comorbidities. As a GLP-1R biased agonist, ASC30 and its formulations, including ASC30 A1, activate the GLP-1 receptor to stimulate insulin secretion and promote weight loss, but do so *without β-arrestin recruitment*, distinguishing it mechanistically from other agents in the class. ASC30 A1 demonstrates a *flatter pharmacokinetic profile* compared to the original ASC30 tablet, potentially supporting more consistent drug exposure. Both formulations are being evaluated in clinical trials for weight loss efficacy, safety, and tolerability. The program leverages once-daily oral dosing to provide a patient-friendly alternative to injectable GLP-1 agonists[3][4][6][7].

Other names

ASC30 A1ASC-30 A1ASC 30 A1ASC30 tablets A1ASC-30 tablets A1ASC 30 tablets A1